Skip to main content

Secondary findings in hereditary breast and ovarian cancer predisposition genes in 5070 Polish non-oncological exomes

In brief

Clinical exomes found hereditary breast and ovarian cancer variants in 7.1%

In 5,070 non-oncology exomes from Poland, 7.1% had a pathogenic or likely pathogenic finding in a hereditary breast or ovarian cancer predisposition gene - about 1 in 14. More than half of findings were in genes outside the ACMG secondary findings framework, showing that its list does not capture the full range found in clinical exomes; the study does not establish how often these results changed care.

Journal
European journal of human genetics : EJHG (Q1)
Published
20 November 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Ewa Czukiewska, Dominika Szczęśniak, Małgorzata Nowak-Kępczyk, Tymoteusz Czukiewski, Jacek Kiś, Magdalena Mroczek, et al.
PMID
43064777
DOI
10.1038/s41431-026-02270-z

Why clinicians should know about it

  • Picked for Genetics (clinical) (top studies of the week, 22 November 2026): Clinically actionable hereditary cancer findings from exomes

Abstract

Whole-exome sequencing (WES) enables identification of medically actionable hereditary cancer predisposition findings beyond the primary diagnostic indication. We performed a retrospective analysis of 5100 clinical WES tests. After exclusion of 30 oncology-related cases, a non-oncological cohort of 5070 WES tests was used to evaluate pathogenic and likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes. A variant-level dataset comprised 151 unique pathogenic or likely pathogenic variants. The overall detection frequency of pathogenic or likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes was 7.1%. The highest gene-level frequencies were observed for CHEK2 (1.54%), ATM (1.34%), BRCA2 (0.75%), BRCA1 (0.61%) and PALB2 (0.59%). Moderate-penetrance hereditary cancer genes accounted for 3.81% of the cohort, slightly exceeding the frequency observed for high-penetrance hereditary cancer and Lynch syndrome-associated genes (3.33%). Among genes included in the ACMG secondary findings framework, BRCA2, BRCA1, and mismatch repair genes accounted for most secondary findings, whereas PTEN and NF1 findings were predominantly phenotype-driven. Of the pathogenic and likely pathogenic findings, 46.7% occurred in genes included in the ACMG Secondary Findings framework, whereas 53.3% occurred in other hereditary cancer predisposition genes analysed in this study. This distribution reflects the deliberately selective scope of the ACMG SF framework and the broader spectrum of hereditary cancer susceptibility findings that may be encountered in clinical WES.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.